GeoVax Labs Inc. and City of Hope entered into a license agreement granting GeoVax exclusive rights to further develop and commercialize COH04S1, a multi-antigenic SARS-CoV-2 investigational vaccine developed at City of Hope for immunocompromised patients.
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have pinpointed a combination immunotherapy treatment that enhances the immune response for people with malignant gliomas, an aggressive type of brain tumor that is fast growing and difficult to treat.
